ALLMedicine™ Hemolytic-uremic Syndrome Center

Mar 28th, 2021 - Atypical hemolytic and uremic syndrome (aHUS), a thrombotic micro-angiopathy (TMA) caused by deregulation in the complement pathway, is sometimes due to the presence of anti-complement factor H (CFH) auto-antibodies. The "standard" treatment for s...

Feb 13th, 2021 - Acute severe neurologic involvement is the most threatening complication in children with hemolytic-uremic syndrome (HUS). Our primary study objectives were to describe the association between acute neurologic manifestations (ANMs) and in-hospital...

Dec 3rd, 2020 - The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter open-label study to assess eculizumab discontinuation in children and a...

Oct 10th, 2020 - This is a novel case of a 16-month-old boy with a history of prematurity with intrauterine growth restriction, severe failure to thrive, microcephaly, pachygyria, agenesis of the corpus callosum, and postnatal embolic stroke, who presented with ne...

Jul 27th, 2020 - Shiga toxin-producing Escherichia coli (STEC) infections result in a significant public health impact because of the severity of the disease that, in young children especially, can lead to hemolytic-uremic syndrome (HUS). A rise in the number of H...

Mar 28th, 2021 - Atypical hemolytic and uremic syndrome (aHUS), a thrombotic micro-angiopathy (TMA) caused by deregulation in the complement pathway, is sometimes due to the presence of anti-complement factor H (CFH) auto-antibodies. The "standard" treatment for s...

Feb 13th, 2021 - Acute severe neurologic involvement is the most threatening complication in children with hemolytic-uremic syndrome (HUS). Our primary study objectives were to describe the association between acute neurologic manifestations (ANMs) and in-hospital...

Dec 3rd, 2020 - The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter open-label study to assess eculizumab discontinuation in children and a...

Oct 10th, 2020 - This is a novel case of a 16-month-old boy with a history of prematurity with intrauterine growth restriction, severe failure to thrive, microcephaly, pachygyria, agenesis of the corpus callosum, and postnatal embolic stroke, who presented with ne...

Jul 27th, 2020 - Shiga toxin-producing Escherichia coli (STEC) infections result in a significant public health impact because of the severity of the disease that, in young children especially, can lead to hemolytic-uremic syndrome (HUS). A rise in the number of H...

Sep 12th, 2018 - CAIRO (Reuters) - Egypt’s public prosecutor said on Wednesday that e-coli bacteria were a factor in the deaths of two British tourists in the Red Sea resort of Hurghada last month. FILE PHOTO: A view of the Red Sea resort of Hurghada, Egypt, Augus...

Nov 4th, 2014 - A few months ago, a nephrologist called me about a young, previously healthy health care worker who presented with an altered mental status, rapidly progressive renal failure, and rhabdomyolysis. It was an unusual combination of symptoms, and he h.

Jun 5th, 2013 - Action Points Long-term treatment with the humanized monoclonal antibody eculizumab was highly effective in thwarting thrombotic microangiopathy and improving kidney function in atypical hemolytic-uremic syndrome. Point out that unlike the more co...

Jun 6th, 2012 - June 7, 2012 (Paris, France) — Children with atypical hemolytic-uremic syndrome (aHUS) had a robust response to eculizumab (Soliris) in real-life clinical settings. The finding mirrors clinical trial results reported for adults and teens. Therese ...

Oct 27th, 2011 - Action Points Explain that the large outbreak of Escherichia coli-associated foodborne illness in Germany this past spring, ultimately traced to raw sprouts, was caused by an unusual strain of the pathogen, and resulted in a unique pattern of clin...